Switching between parathormone (PTH) assays: The impact on the diagnosis of renal osteodystrophy

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 6, 2013, Pages 1251-1256

  Beko, Gabriella ^a   Butz, Henriett ^a   Berta, Klára ^b   Tislér, András ^a   Olajos, Ferenc ^a   Vásárhelyi, Barna ^a   Patócs, Attila ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Fresenius Medical Care   (Hungary)

Author keywords

Chronic kidney disease; Dialysis; Intact PTH; Parathormone (PTH) measurement; PTH(1 84); Secondary hyperparathyroidism

Indexed keywords

PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIALYSIS; DISEASE CLASSIFICATION; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PRACTICE GUIDELINES AS TOPIC; RENAL OSTEODYSTROPHY; YOUNG ADULT;

EID: 84882383100     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0485     Document Type: Article

References (20)

1. Friedman PA, Goodman WG. PTH (1-84)/PTH (7-84): a balance of power. Am J Physiol Renal Physiol 2006;290:F975-84.
2. Stokes FJ, Ivanov P, Bailey LM, Fraser WD. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011;57:138-40.
3. Sturgeon CM, Seth J. Why do immunoassays for tumour markers give differing results? A view from the UK National External Quality Assessment Schemes. Eur J Clin Chem Clin Biochem 1996;34:755-9.
4. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in secondgeneration assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008;51:987-95.
5. Torres PU. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006;70:240-3.
6. National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance 117. Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Patients with End-Stage Renal Disease on Maintenance Dialysis Therapy, 2007. Available from: http://guidance.nice.org.uk/nicemedia/ live/11608/33857/33857.pdf. Accessed 10 January, 2011.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;113:S1-130.
8. Steddon S, Sharples E. Renal Association Clinical Practice Guideline: CKD-Mineral and Bone Disorders (CKD-MBD), 2011. Available from: http://www.renal.org/clinical/Guidelines-Section/CKD-MBD.aspx. Accessed 10 September.
9. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
10. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease 2003. Am J Kidney Dis 2003;42:S1-201.
11. Waller S, Ridout D, Cantor T, Rees L. Differences between " intact " PTH and 1-84 PTH assays in chronic renal failure and dialysis. Pediatr Nephrol 2005;20:197-9.
12. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84:implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14.
13. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-90.
14. La'ulu SL, Roberts WL. Performance characteristics of six intact parathyroid hormone assays. Am J Clin Pathol 2010;134:930-8.
15. Taniguchi M, Tanaka M, Hamano T, Nakanishi S, Fujii H, Kato H, et al. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 2011;15(Suppl 1):42-9.
16. Almond A, Ellis AR, Walker SW. On behalf of the scottish clinical biochemistry managed diagnostic network. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012;49:63-7.
17. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results-a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440-5.
18. Souberbielle J-C, Cavalier E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med 2010;48:769-74.
19. Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006;52:1771-6.
20. Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012;27:1950-6.